0001562180-21-000562.txt : 20210127
0001562180-21-000562.hdr.sgml : 20210127
20210127161910
ACCESSION NUMBER: 0001562180-21-000562
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210125
FILED AS OF DATE: 20210127
DATE AS OF CHANGE: 20210127
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mills Kenneth T.
CENTRAL INDEX KEY: 0001652824
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37553
FILM NUMBER: 21559964
MAIL ADDRESS:
STREET 1: C/O REGENXBIO INC.
STREET 2: 9600 BLACKWELL ROAD, SUITE 210
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENXBIO Inc.
CENTRAL INDEX KEY: 0001590877
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 471851754
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9600 BLACKWELL ROAD
STREET 2: SUITE 210
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: 240-552-8181
MAIL ADDRESS:
STREET 1: 9600 BLACKWELL ROAD
STREET 2: SUITE 210
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
FORMER COMPANY:
FORMER CONFORMED NAME: REGENXBIO, Inc.
DATE OF NAME CHANGE: 20150116
FORMER COMPANY:
FORMER CONFORMED NAME: ReGenX Biosciences, LLC
DATE OF NAME CHANGE: 20131101
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2021-01-25
false
0001590877
REGENXBIO Inc.
RGNX
0001652824
Mills Kenneth T.
C/O REGENXBIO INC.
9600 BLACKWELL ROAD, SUITE 210
ROCKVILLE
MD
20850
true
true
false
false
President and CEO
Common Stock
2021-01-25
4
M
false
6500.00
0.85
A
287484.00
D
Common Stock
2021-01-25
4
S
false
315.00
42.64
D
287169.00
D
Common Stock
2021-01-25
4
S
false
974.00
44.05
D
286195.00
D
Common Stock
2021-01-25
4
S
false
5211.00
44.99
D
280984.00
D
Employee Stock Option (Right to Buy)
0.85
2021-01-25
4
M
false
6500.00
0.00
D
2024-09-23
Common Stock
6500.00
41170.00
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan.
This transaction was executed in multiple trades at prices ranging from $42.49 to $42.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $43.55 to $44.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $44.55 to $45.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The previously granted option, representing a right to purchase a total of 708,200 shares, became exercisable as follows: 474,490 of the shares subject to the option are initial shares ("Initial Shares") and 233,710 of the shares subject to the option are contingent shares ("Contingent Shares"). 120,394 of the Initial Shares vested on September 17, 2014, 88,524 of the Initial Shares vested on September 17, 2015 and an additional 7,377 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter.
/s/ Patrick J. Christmas as attorney-in-fact
2021-01-27